文献速递慢性肾脏病

白蛋白尿变化与GFR斜率作为肾衰竭联合替代终点:对慢性肾脏病2期临床试验的启示

Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD.
PubMed 文献 · J Am Soc Nephrol · 2023-03-15

该研究基于41项随机试验的贝叶斯荟萃回归,分析治疗对尿白蛋白肌酐比(UACR)变化和GFR斜率的联合效应与临床终点(血清肌酐持续加倍、GFR<15 ml/min/1.73 m²或肾衰竭)的关系。结果显示,在每臂100-200例、随访1-2年的2期试验中,联合两种替代终点可改善对临床终点治疗效应的预测。

要点

  • 治疗对UACR变化和慢性GFR斜率的联合效应与临床终点治疗效应强相关。
  • 样本量小(约每臂60例)且随访短(约1年)时,预测概率主要取决于UACR效应。
  • 样本量较大、随访较长时,GFR斜率的重要性增加。

核心结论

  • 在每臂100-200例、随访1-2年的CKD 2期试验中,联合UACR变化和GFR斜率的治疗效应信息可改善对临床终点治疗效应的预测。

研究设计与样本

  • 基于41项CKD进展随机试验的贝叶斯荟萃回归分析。

主要发现

  • 治疗对临床终点的效应与UACR变化和慢性GFR斜率的联合治疗效应强相关。
  • GFR斜率治疗效应的后验中位荟萃回归系数为-0.41(95%贝叶斯可信区间-0.64至-0.17)/(1 ml/min/1.73 m²/年)。
  • UACR变化治疗效应的后验中位荟萃回归系数为-0.06(95%贝叶斯可信区间-0.90至0.77)。
  • 样本量小(约每臂60例)且随访短(约1年)时,预测临床获益概率主要取决于UACR的估计治疗效应。
  • 样本量较大和随访较长时,GFR斜率的重要性增加。

关键数值与推荐

  • 临床终点定义为血清肌酐持续加倍、GFR<15 ml/min/1.73 m²或肾衰竭。
  • 在每臂100-200例、随访1-2年的2期试验中,联合UACR变化和GFR斜率信息可改善预测。

临床怎么用

  • 这些发现可能有助于为旨在减缓CKD进展的干预措施设计临床试验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: Changes in albuminuria and GFR slope are individually used as surrogate end points in clinical trials of CKD progression, and studies have demonstrated that each is associated with treatment effects on clinical end points. In this study, the authors sought to develop a conceptual framework that combines both surrogate end points to better predict treatment effects on clinical end points in Phase 2 trials. The results demonstrate that information from the combined treatment effects on albuminuria and GFR slope improves the prediction of treatment effects on the clinical end point for Phase 2 trials with sample sizes between 100 and 200 patients and duration of follow-up ranging from 1 to 2 years. These findings may help inform design of clinical trials for interventions aimed at slowing CKD progression. BACKGROUND: Changes in log urinary albumin-to-creatinine ratio (UACR) and GFR slope are individually used as surrogate end points in clinical trials of CKD progression. Whether combining these surrogate end points might strengthen inferences about clinical benefit is unknown. METHODS: Using Bayesian meta-regressions across 41 randomized trials of CKD progression, we characterized the combined relationship between the treatment effects on the clinical end point (sustained doubling of serum creatinine, GFR <15 ml/min per 1.73 m 2 , or kidney failure) and treatment effects on UACR change and chronic GFR slope after 3 months. We applied the results to the design of Phase 2 trials on the basis of UACR change and chronic GFR slope in combination. RESULTS: Treatment effects on the clinical end point were strongly associated with the combination of treatment effects on UACR change and chronic slope. The posterior median meta-regression coefficients for treatment effects were -0.41 (95% Bayesian Credible Interval, -0.64 to -0.17) per 1 ml/min per 1.73 m 2 per year for the treatment effect on GFR slope and -0.06 (95% Bayesian Credible Interval, -0.90 to 0.77) for the treatment effect on UACR change. The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up. CONCLUSIONS: In Phase 2 trials of CKD with sample sizes of 100-200 patients per arm and follow-up between 1 and 2 years, combining information from treatment effects on UACR change and GFR slope improved the prediction of treatment effects on clinical end points.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Inker LA, Tighiouart H, et al. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD. J Am Soc Nephrol. 2023. PMID: 36918388. doi:10.1681/ASN.0000000000000117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。